Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$17M
- −122.7% YoY · −55.7% QoQ
- EPS (diluted)
- −$0.21
- −143.8% YoY · −61.5% QoQ
Source: XBRL data from the Eledon Pharmaceuticals, Inc. (ELDN) Q3 2025 10-Q on SEC EDGAR. USD.
Eledon Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, or net-income percentages disclosed in provided MD&A
- BESTOW eGFR approximately $69 mL/min/1.73 m² vs $66 for tacrolimus at 12 months
- Tegoprubart rejection rate 20.6% vs tacrolimus 14.1%; efficacy failure 22% vs 17%
- ALS development requires additional financing; kidney transplantation remains the priority
Risk Factors
- Strategic reset risk: Anelixis acquisition and discontinuation of islet-cell transplantation and IgAN programs changed future prospects from historical periods
- Liquidity risk: $93.4 million cash and short-term investments, but insufficient funding for continued ALS tegoprubart development
- Dilution risk: 2025 offering added 19,698,085 shares and warrants for 15,151,515 shares
- Regulatory risk: FDA rulemaking pause under a Trump administration Executive Order could delay development and commercialization activities
- Banking risk: FDIC-insured accounts held less than 3% of cash and short-term investments after Silicon Valley Bank’s 2023 failure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eledon Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.